IBRX catalyst calendar

ImmunityBio, Inc.

Upcoming catalysts
16
Cash runway
14.2 months
Cash & investments
$357M
Phase 3 programs
5

ImmunityBio, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is A Study to Assess Anktiva in Patients With Long Covid-19. on October 15, 2026. There are 16 upcoming events on record.

Cash runway is approximately 14.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 59 concluded trials, 31% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 15, 2026 A Study to Assess Anktiva in Patients With Long Covid-19. Trial Milestone Phase 2
November 15, 2026 Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer Trial Milestone Phase 2
March 15, 2027 A Study to Examine Anktiva for the Treatment of COVID-19. Trial Milestone Phase 2
May 15, 2027 A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer Trial Milestone Phase 2
May 25, 2027 Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma Trial Milestone Phase 2
August 3, 2027 NAI for Sepsis With Persistent Lymphopenia Trial Milestone Phase 2
September 2, 2027 IBRX-042 In Participants With HPV-Associated Tumors Trial Milestone Phase 1
October 15, 2027 Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma Trial Milestone Phase 1
December 15, 2027 Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma Trial Milestone Phase 2
January 15, 2028 N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer Trial Milestone Phase 1
February 15, 2028 ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG Trial Milestone Phase 1/Phase 2
May 12, 2028 NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis Trial Milestone Phase 2
September 15, 2028 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In Trial Milestone Phase 3
August 31, 2029 QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors Trial Milestone Phase 2
December 31, 2029 N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma Trial Milestone Phase 2
December 31, 2030 Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation Trial Milestone Phase 2

Track IBRX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open IBRX in the tracker

Recent history

DateEventTypePhase
September 30, 2026 A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer Trial Milestone Phase 1/Phase 2
August 4, 2026 Quarterly results filed (8-K) Earnings —
July 30, 2026 8-K filed: Reg FD disclosure Filing —
July 1, 2026 A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia Trial Milestone Phase 1
May 31, 2026 QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors Trial Milestone Phase 1
May 18, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
May 15, 2026 Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma Trial Milestone Phase 1
May 7, 2026 Quarterly results filed (8-K) Earnings —
April 9, 2026 Quarterly results filed (8-K) Earnings —
April 6, 2026 8-K filed: Reg FD disclosure Filing —
March 31, 2026 8-K filed: Material agreement, Reg FD disclosure, Other event Corporate —
February 23, 2026 Quarterly results filed (8-K) Earnings —
February 18, 2026 8-K filed: Other event Filing —
January 26, 2026 8-K filed: Material agreement Corporate —
January 15, 2026 Quarterly results filed (8-K) Earnings —
January 14, 2026 8-K filed: Other event Filing —
December 29, 2025 8-K filed: Material agreement, Other event Corporate —
December 15, 2025 8-K filed: Leadership change Corporate —
December 12, 2025 8-K filed: Other event Filing —
November 5, 2025 Quarterly results filed (8-K) Earnings —
October 13, 2025 Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer Trial Milestone Phase 2
October 13, 2025 Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer Trial Milestone Phase 3
August 8, 2025 8-K filed: Other event Filing —
August 5, 2025 Quarterly results filed (8-K) Earnings —
July 25, 2025 Quarterly results filed (8-K) Earnings —
June 20, 2025 8-K filed: Leadership change Corporate —
May 12, 2025 Quarterly results filed (8-K) Earnings —
May 5, 2025 8-K filed: Other event Filing —
April 15, 2025 Quarterly results filed (8-K) Earnings —
February 15, 2025 HCW9218 for Advanced Pancreatic Cancer Trial Milestone Phase 1/Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.